Hematologic Diseases D006402

Diseases [C] » Hemic and Lymphatic Diseases [C15] » Hematologic Diseases

Description

Disorders of the blood and blood forming tissues.   MeSH

Subtype Terms (18)

Anemia
279 drugs (176 approved, 103 experimental)

Blood Coagulation Disorders
25 drugs (20 approved, 5 experimental)

Blood Platelet Disorders
43 drugs (28 approved, 15 experimental)

Blood Protein Disorders
6 drugs (5 approved, 1 experimental)

Bone Marrow Diseases
47 drugs (36 approved, 11 experimental)

Erythroblastosis, Fetal
4 drugs (3 approved, 1 experimental)

Hematologic Neoplasms
256 drugs (119 approved, 137 experimental)

Hemoglobinopathies
39 drugs (24 approved, 15 experimental)

Hemorrhagic Disorders
13 drugs (6 approved, 7 experimental)

Leukocyte Disorders
3 drugs (2 approved, 1 experimental)

Methemoglobinemia
6 drugs (5 approved, 1 experimental)

Pancytopenia
11 drugs (7 approved, 4 experimental)

Polycythemia
7 drugs (6 approved, 1 experimental)

Pregnancy Complications, Hematologic
2 approved drugs

Preleukemia
10 drugs (7 approved, 3 experimental)

Sulfhemoglobinemia
 

Thrombophilia
10 drugs (6 approved, 4 experimental)

Transfusion Reaction
10 drugs (7 approved, 3 experimental)


Approved Indicated Drugs (1)


Organization Involved with Phase 3 Indications (62)

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.